Loading clinical trials...
Loading clinical trials...
Observational, Real-world, Digital Biomarker, and Integrated Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
This study is an observational, ambispective, descriptive, non-interventional study of people with a chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (CIDP) diagnosis in the United States with residual impairment, disability, or neurological deficits after at least three months of treatment with standard of care therapy. The study is expected to last two years. Enrollment is expected to continue for one year. Depending on when the participant is enrolled, a participant can be followed for between one and two years, through the end of study, approximately two years after the study starts.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Investigational Site
Swiftwater, Pennsylvania, United States
Start Date
April 11, 2025
Primary Completion Date
May 17, 2027
Completion Date
May 17, 2027
Last Updated
June 29, 2025
200
ESTIMATED participants
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
800-633-1610contact-us@sanofi.comLead Sponsor
Sanofi
NCT06859099
NCT01847937
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions